ArticleOrphanet journal of rare diseases2025

The EMA as a potential driver of competitiveness of orphan medicines in Europe: a focus on regulatory incentives and funding opportunities.

Maria Ana Gomez-Ferreria et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.